Psoriasis News

Home-based phototherapy proved effective for the treatment of plaque and guttate psoriasis across skin types, providing a convenient therapy method for patients, according to a study.

The FDA has approved 320 mg pre-filled syringes and autoinjectors of Bimzelx for the treatment of active psoriatic arthritis with coexisting moderate-to-severe plaque psoriasis, according to a press release from UCB.

ICP-488 demonstrated “excellent” efficacy and safety for the treatment of moderate to severe plaque psoriasis in adults, InnoCare Pharma announced in a press release.

The FDA has approved the Stelara biosimilar, Imuldosa, for Crohn’s disease, ulcerative colitis and all other indications of the reference product, and the latest addition to the Stelara biosimilar bottleneck set to release in 2025.

Patients with scalp and palmoplantar psoriasis treated with bimekizumab had a high rate of clearance maintained through 4 years of treatment, according to a poster presented at the European Academy of Dermatology and Venereology Congress.

ESK-001 demonstrates continued efficacy for the treatment of moderate to severe plaque psoriasis over the span of 7 months, according to a late-breaker presentation at the European Academy of Dermatology and Venereology Congress.

A new study further confirmed the association between obsessive-compulsive disorder and psoriasis, stressing the need for dermatologists to be vigilant.

NEW YORK — At the Skin of Color Update 2024 meeting, a speaker discussed how to diagnose and treat nail psoriasis and nail lichen planus in patients with skin of color.

Risankizumab showed a significant improvement in psoriasis severity and quality of life in biologic-naïve patients and in those previously treated with other biologics, according to a study.

Deucravacitinib proved to be efficacious in the treatment of moderate to severe scalp psoriasis and less extensive overall psoriasis, according to two presentations at the European Academy of Dermatology and Venerology Congress.